According to filings with the U.S. Securities and Exchange Commission, MapLight Therapeutics is raising up to $372,449,989.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About MapLight Therapeutics
Neurological and neuropsychiatric disorders strike at the very core of our identity, and inflict higher treatment and productivity costs than cancer, cardiovascular disease, and diabetes combined. Years of life are lost for these patients, and many face the future with a severe disability that impedes everyday living. While therapeutic options exist, many patients remain untreated or inadequately treated, and continue to live with persistent, disabling symptoms. More treatment options are needed to support patients living with CNS disorders. Despite the unmet need, bringing truly innovative treatments to patients with CNS conditions has been challenging. Antipsychotic drugs widely-used today are mechanistically similar to their 1950s prototypes and with good reason. Changing brain function in specific, targeted ways is far from simple, due to the astounding complexity of cell types and their interconnections in the nervous system.

To learn more about MapLight Therapeutics, visit https://maplightrx.com/
MapLight Therapeutics Linkedin Page: https://www.linkedin.com/company/maplight-therapeutics-inc/

Contact:
Christopher Kroeger, Chief Executive Officer
650-839-4360
https://www.linkedin.com/in/chriskroeger/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.